Anti-thrombotic effect of a PAI-1 inhibitor in rats given endotoxin

Thrombosis and Haemostasis

Volumn 75, Issue 1, 1996, Pages 118-126

  Abrahamsson, T ^a   Nerme, V ^a   Stromqvist M ^a   Akerblom B ^a   Legnehed, A ^a   Pettersson, K ^a   Westin Eriksson, A ^a  

^a ASTRAZENECA R AND D   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BATROXOBIN; ENDOTOXIN; FIBRIN; FIBRINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1;

ANIMAL EXPERIMENT; ARTICLE; BLOOD CLOT LYSIS; CONTROLLED STUDY; EUGLOBULIN LYSIS TEST; FIBRIN CLOT; FIBRIN FORMATION; LUNG; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 0030034227     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1650231     Document Type: Article

References (40)

1. Kruithof EKO. Plasminogen activator inhibitor type 1: Biochemical, biological and clinical aspects. Fibrinolysis 1988; 2 (suppl 2): 59-70.
2. Wiman B, Hamsten A. The fibrinolytic enzyme system and its role in the etiology of thromboembolic disease. Semin Thromb Hemost 1990; 16: 207-16.
3. Aznar J, Estellés J. Roles of plasminogen activator inhibitor type 1 in the pathogenesis of coronary artery diseases. Haemostasis 1994; 24: 243-51.
4. Rocha E, Páramo JA. The relationship between impaired fibrinolysis and coronary heart disease: a role for PAI-1. Fibrinolysis 1994; 8: 294-303.
5. Krishnamurti C, Barr CF, Hassett MA, Young GD, Alving BM. Plasminogen activator inhibitor: a regulator of ancrod-induced fibrin deposition in rabbits. Blood 1987; 69: 798-803.
6. Reilly CF, Fujita T, Mayer EF, Siegfried ME. Both circulating and clotbound plasminogen activator inhibitor-1 inhibit endogenous fibrinolysis in the rat. Arterioscler Thromb 1991; 11: 1276-86.
7. Carmeliet P, Stassen JM, Schoonjans L, Ream B, van de Oord JJ, De Mol M, Mulligan RC, Collen D. Plasminogen activator inhibitor-1 gene-deficient mice. J Clin Invest 1993; 92: 2756-60.
8. Levi M, Biemond BJ, van Zonnenveld AJ, ten Cate JW, Pannekoek H. Inhibition of plasminogen activator inhibitor-1 activity results in promotion of endogenous thrombolysis and inhibition of thrombus extension in models of experimental thrombosis. Circulation 1992; 85: 305-12.
9. Biemond BJ, Levi M, Coronel R, Janse MJ, ten Cate JW, Pannekoek H. Thrombolysis and reocclusion in experimental jugular vein and coronary artery thrombosis: effects of a plasminogen activator inhibitor type 1 neutralizing monoclonal antibody. Circulation 1995; 91: 1175-81.
10. Emeis JJ, Kooistra T. Interleukin and lipopolysaccharide induce an inhibitor of tissue-type plasminogen activator in vivo and in cultured endothelial cells. J Exp Med 1986; 163: 1260-6.
11. Suffredini A, Harpel PC, Parrillo JE. Promotion and subsequent inhibition of plasminogen activation after administration of intravenous endotoxin to normal subjects. N Engl J Med 1989; 320: 1165-72.
12. Levi M, ten Cate H, Bauer KA, van der Poll T, Edgington TS, Büler HR, van Deventer SJH, Hack CE, ten Cate JW, Rosenberg RD. Inhibition of endotoxm-induced activation of coagulation and fibrinolysis by pentoxifylline or by a monoclonal anti-tissue factor antibody in chimpanzees. J Clin Invest 1994; 93: 114-20.
13. Pádro T, Quax PHA, van den Hoogen CM, Roholl P, Verheijen JH, Emeis JJ. Tissue-type plasminogen activator and its inhibitor in rat aorta. Arterioscler Thromb 1994; 14: 1459-65.
14. Pirkle H, Stocker K. Thrombin-like enzymes from snake venoms: An inventory. Thromb Haemost 1991; 65: 444-50.
15. Kwaan HC, Barlow GH. The mechanisms of action of arvin and reptilase. Thrombos Diathes Haemorrh 1971; 47 (suppl 1): 361-9.
16. Pizzo SV, Schwartz ML, Hill RL, McKee PA. Mechanism of ancrod anti-coagulation. A direct proteolytic effect on fibrin J Clin Invest 1972; 51: 2841-50.
17. 131I. J Clin Invest 1966; 45: 1202-12.
18. Klöcking HP, Markwardt F, Güttner J. On the mechanism of batroxobin-induced fibrinolysis. Pharmazie 1989; 44: 504-5.
19. Strömqvist M, Andersson J-O, Boström S, Deinum J, Ehnebom J, Enquist K, Johansson T, Hansson L. Separation of active and inactive forms of recombinant human plasminogen activator inhibitor type1 (PAI-1) expressed in Chinese hamster ovary cells: Comparison with native human PAI-1. Protein Express Purif 1994; 5: 309-16.
20. Gallimore MJ, Tyler HM, Shaw JTB. The measurement of fibrinolysis in the rat. Thrombos Diathes Haemorrh 1971; 26: 295-310.
21. Chmielewska J, Rånby M, Wiman B. Evidence for a rapid inhibitor to tissue plasminogen activator in plasma Thromb Res 1983; 31: 427-36.
22. Axenborg J, Hirsch I. A PC-based on-line system for physiological in vivo and in vitro experiments. Comp Methods Progr Biomed 1993; 41: 55-67.
23. Longstaff C. Studies on the mechanism of action of aprotinin and tranexamic acid as plasmin inhibitors and antifibrinolytic agents. Blood Coag Fibrinol 1994; 5: 537-42.
24. Regoeczi E, Brain MC. Organ distribution of fibrin in disseminated intravascular coagulation. Brit J Haemat 1969; 17: 73-81.
25. Lenfors S, Marberg L, Wikström S, Jonsson U, Westin-Eriksson A, Gustafsson D. A new rat model of arterial thrombosis with a platelet-rich head and an erythrocyte-rich tail: thrombolysis experiments with specific thrombin inhibition. Blood Coag Fibrinol 1993; 4: 263-71.
26. Green CJ. Animal anaesthesia. Laboratory animals Ltd, London 1979.
27. Schneider DJ, Nordt TK, Sobel BE. Attenuated fibrinolysis and accelerated atherogenesis in type II diabetic patients. Diabetes 1993; 42; 1-7.
28. Juhan-Vague I, Alessi MC. Plasminogen activator inhibitor-1 and atherothrombosis. Thromb Haemost 1993; 70: 138-43.
29. Eriksson BI, Eriksson E, Gyzander E, Teger-Nilsson A-C, Risberg B. Thrombosis after hip replacement. Relationship to the fibrinolytic system. Acta Orthop Scand 1989; 60: 159-63.
30. Eriksson BI, Eriksson E, Risberg B. Impaired fibrinolysis and postoperative thrombo-embolism in orthopedic patients. Thromb Res 1991; 1-2: 55-64.
31. Hamsten A, Wiman B, de Faire U, Blombäck M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med 1985; 313: 1557-63.
32. Masuda T, Yasue H, Ogawa H, Misumi I, Sakamoto T, Okubo H, Miyao Y, Kato H. Plasma plasminogen activator inhibitor activity and tissue plasminogen activator levels in patients with unstable angina and those with coronary spastic angina. Am Heart J 1992; 124: 314-9.
33. Ihnken K, Speiser W, Ruf W, Thiel W, Schlepper M, Müller-Berghaus G. High PAI activity with correlation to triglyceride and HDL cholesterol values in patients with coronary artery disease with no difference in survivors of myocardial infarction. Ann Hematol 1993; 67: 237-44.
34. Schneiderman J, Sawdey MS, Keeton MR, Bordin GM, Bernstein EF, Dilley RB, Loskutoff DJ. Increased type 1 plasminogen activator inhibitor gene expression in athersclerotic human arteries. Proc Natl Acad Sci 1992; 89: 6998-7002.
35. Stringer HAR, van Swieten P, Heijnen HFG, Sixma JJ, Pannekoek H. Plasminogen activator inhibitor-1 released from activated platelets plays a key role in thrombolysis resistance. Arterioscler Thromb 1994; 14: 1452-8.
36. Moore KL, Andreoli SP, Esmon NL, Esmon CT, Bang NU. Endotoxin enhances tissue factor and suppresses thrombomodulin expression of human vascular endothelium in vitro. J Clin Invest 1987; 79: 124-30.
37. Pralong G, Calandra T, Glauser MP, Schellekens J, Verhoef J, Bachmann F, Kruithof EKO. Plasminogen activator inhibitor 1: A new prognostic marker in septic shock. Thromb Haemost 1989; 61: 459-62.
38. Colucci M, Paramo JA, Stassen JM, Collen D. Influence of the fast-acting inhibitor of plasminogen activator on in vivo thrombolysis induced by tissue-type plasminogen activator in rabbits. Interference of tissue-derived components. J Clin Invest 1986; 78: 138-44.
39. Krishnamurti C, Young GD, Barr CF, Colleton CA, Alving BM. Enhancement of tissue plasminogen activator-induced fibrinolysis by activated protein C in endotoxin-treated rabbits. J Lab Clin Med 1991; 118: 523-30.
40. Saldeen T. Quantitative determination of intravascular coagulation in the lungs of experimental animals. Scand J Haemat 1969; 6: 205-15.